NYSE:GMED Globus Medical (GMED) Stock Forecast, Price & News $52.93 -0.14 (-0.26%) (As of 05/26/2023 07:00 PM ET) Add Compare Share Share Today's Range$52.66▼$53.5450-Day Range$52.26▼$59.0352-Week Range$50.92▼$80.04Volume1.24 million shsAverage Volume1.44 million shsMarket Capitalization$5.31 billionP/E Ratio26.87Dividend YieldN/APrice Target$70.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Globus Medical MarketRank™ ForecastAnalyst RatingHold2.18 Rating ScoreUpside/Downside33.2% Upside$70.50 Price TargetShort InterestBearish9.99% of Float Sold ShortDividend StrengthN/ASustainability-0.93Upright™ Environmental ScoreNews Sentiment0.51Based on 8 Articles This WeekInsider TradingSelling Shares$2.48 M Sold Last QuarterProj. Earnings Growth10.78%From $2.32 to $2.57 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.60 out of 5 starsMedical Sector140th out of 1,010 stocksSurgical & Medical Instruments Industry14th out of 104 stocks 3.1 Analyst's Opinion Consensus RatingGlobus Medical has received a consensus rating of Hold. The company's average rating score is 2.18, and is based on 3 buy ratings, 7 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $70.50, Globus Medical has a forecasted upside of 33.2% from its current price of $52.93.Amount of Analyst CoverageGlobus Medical has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.99% of the float of Globus Medical has been sold short.Short Interest Ratio / Days to CoverGlobus Medical has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Globus Medical has recently increased by 23.99%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGlobus Medical does not currently pay a dividend.Dividend GrowthGlobus Medical does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGlobus Medical has received a 57.33% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Neurostimulators", "Synthetic bone grafts", "Artificial joints", and "Robotic surgery systems" products. See details.Environmental SustainabilityThe Environmental Impact score for Globus Medical is -0.93. Previous Next 2.5 News and Social Media Coverage News SentimentGlobus Medical has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Globus Medical this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for GMED on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows2 people have added Globus Medical to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Globus Medical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,475,781.00 in company stock.Percentage Held by Insiders24.41% of the stock of Globus Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions74.23% of the stock of Globus Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Globus Medical are expected to grow by 10.78% in the coming year, from $2.32 to $2.57 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Globus Medical is 26.87, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 132.67.Price to Earnings Ratio vs. SectorThe P/E ratio of Globus Medical is 26.87, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 120.59.Price to Earnings Growth RatioGlobus Medical has a PEG Ratio of 1.80. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGlobus Medical has a P/B Ratio of 2.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Globus Medical (NYSE:GMED) StockGlobus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The firm engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments. The company was founded by David C. Paul, David D. Davidar and Andrew Iott in March 2003 and is headquartered in Audubon, PA.Read More Receive GMED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Globus Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address GMED Stock News HeadlinesMay 26, 2023 | americanbankingnews.comBrokerages Set Globus Medical, Inc. (NYSE:GMED) PT at $69.88May 23, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Globus Medical (GMED) and Oncolytics Biotech (ONCY)May 29, 2023 | Stocks To Trade (Ad)Free Daily Trade Alerts. Up to 15 opportunities a day.Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 21, 2023 | finance.yahoo.comIs Globus Medical, Inc. (NYSE:GMED) Potentially Undervalued?May 20, 2023 | americanbankingnews.comInsider Selling: Globus Medical, Inc. (NYSE:GMED) Director Sells $2,475,781.00 in StockMay 15, 2023 | finance.yahoo.comGlobus Medical Announces FDA Approval for its Non-Fusion Scoliosis Correction System, the Latest Advancement for Young Patients with Idiopathic ScoliosisMay 5, 2023 | msn.comTruist Securities Maintains Globus Medical Inc - (GMED) Hold RecommendationMay 5, 2023 | markets.businessinsider.comGlobus Medical (GMED) Receives a Buy from RBC CapitalMay 29, 2023 | Stocks To Trade (Ad)Free Daily Trade Alerts. Up to 15 opportunities a day.Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 5, 2023 | markets.businessinsider.comAnalyst Expectations for Globus Medical's FutureMay 5, 2023 | finance.yahoo.comGlobus Medical (GMED) Q1 2023 Earnings Call TranscriptMay 4, 2023 | msn.comGlobus Medical: Q1 Earnings InsightsMay 4, 2023 | msn.comGlobus Medical (GMED) Surpasses Q1 Earnings and Revenue EstimatesMay 4, 2023 | finance.yahoo.comGlobus Medical Reports First Quarter 2023 ResultsMay 4, 2023 | msn.comGlobus Medical: Still Very Attractive After NuVasive SelloffMay 2, 2023 | americanbankingnews.comGlobus Medical (GMED) to Release Quarterly Earnings on ThursdayMay 1, 2023 | americanbankingnews.comAnalysts Set Globus Medical, Inc. (NYSE:GMED) Target Price at $70.44April 28, 2023 | bizjournals.comGlobus Medical, Nuvasive shareholders approve $3.1B merger dealApril 24, 2023 | finance.yahoo.comGlobus Medical's (NYSE:GMED) investors will be pleased with their 22% return over the last three yearsApril 24, 2023 | bizjournals.comInside the deal: Globus Medical and NuVasive poised to combine in $3.1B mergerApril 17, 2023 | finance.yahoo.comLeading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending NuVasive Shareholders Vote "FOR" the Proposed Merger with Globus MedicalApril 14, 2023 | finance.yahoo.comGlobus' (GMED) NUVA Buyout Seems Strategic, Cost Woe StaysApril 14, 2023 | americanbankingnews.comGlobus Medical (NYSE:GMED) Raised to Buy at StockNews.comApril 14, 2023 | americanbankingnews.comGlobus Medical (NYSE:GMED) Raised to "Buy" at StockNews.comApril 13, 2023 | markets.businessinsider.comSHAREHOLDER UPDATE: Halper Sadeh LLC Investigates TA, GMED, CBIO, AQUAApril 6, 2023 | americanbankingnews.comGlobus Medical, Inc. (NYSE:GMED) Receives $70.44 Consensus Price Target from BrokeragesApril 1, 2023 | americanbankingnews.comGlobus Medical (NYSE:GMED) Rating Reiterated by Canaccord Genuity GroupSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GMED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Globus Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address GMED Company Calendar Last Earnings5/04/2023Today5/29/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNYSE:GMED CUSIP37957720 CIK1237831 Webwww.globusmedical.com Phone(610) 930-1800Fax610-930-2042Employees2,600Year FoundedN/APrice Target and Rating Average Stock Price Forecast$70.50 High Stock Price Forecast$78.00 Low Stock Price Forecast$61.00 Forecasted Upside/Downside+33.2%Consensus RatingHold Rating Score (0-4)2.18 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)$1.97 Trailing P/E Ratio26.87 Forward P/E Ratio22.81 P/E Growth1.8Net Income$190.17 million Net Margins18.82% Pretax Margin24.07% Return on Equity12.26% Return on Assets10.91% Debt Debt-to-Equity RatioN/A Current Ratio6.39 Quick Ratio4.47 Sales & Book Value Annual Sales$759.12 million Price / Sales7.00 Cash Flow$2.85 per share Price / Cash Flow18.59 Book Value$18.43 per share Price / Book2.87Miscellaneous Outstanding Shares100,330,000Free Float75,842,000Market Cap$5.31 billion OptionableOptionable Beta1.06 Key ExecutivesDaniel T. ScavillaPresident, Chief Executive Officer & DirectorKeith W. PfeilCFO, Chief Accounting Officer & Senior VPKelly G. HullerSecretary, Senior VP & General CounselBrian KearnsSenior Vice President-Business DevelopmentKey CompetitorsIntegra LifeSciencesNASDAQ:IARTAtriCureNASDAQ:ATRCNuVasiveNASDAQ:NUVAAlphatecNASDAQ:ATECTeleflexNYSE:TFXView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 1,012 shares on 5/26/2023Ownership: 0.005%Water Island Capital LLCBought 110,300 shares on 5/25/2023Ownership: 0.110%Brandywine Global Investment Management LLCBought 2,585 shares on 5/25/2023Ownership: 0.095%Mint Tower Capital Management B.V.Bought 4,500 shares on 5/24/2023Ownership: 0.004%Seaport Global Advisors LLCSold 4,001 shares on 5/23/2023Ownership: 0.004%View All Insider TransactionsView All Institutional Transactions GMED Stock - Frequently Asked Questions Should I buy or sell Globus Medical stock right now? 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GMED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GMED, but not buy additional shares or sell existing shares. View GMED analyst ratings or view top-rated stocks. What is Globus Medical's stock price forecast for 2023? 11 equities research analysts have issued 1 year price objectives for Globus Medical's stock. Their GMED share price forecasts range from $61.00 to $78.00. On average, they anticipate the company's share price to reach $70.50 in the next year. This suggests a possible upside of 33.2% from the stock's current price. View analysts price targets for GMED or view top-rated stocks among Wall Street analysts. How have GMED shares performed in 2023? Globus Medical's stock was trading at $74.27 at the beginning of the year. Since then, GMED shares have decreased by 28.7% and is now trading at $52.93. View the best growth stocks for 2023 here. Are investors shorting Globus Medical? Globus Medical saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 7,700,000 shares, an increase of 24.0% from the April 30th total of 6,210,000 shares. Based on an average trading volume of 1,460,000 shares, the days-to-cover ratio is currently 5.3 days. Currently, 10.0% of the company's stock are sold short. View Globus Medical's Short Interest. When is Globus Medical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our GMED earnings forecast. How were Globus Medical's earnings last quarter? Globus Medical, Inc. (NYSE:GMED) issued its quarterly earnings data on Thursday, May, 4th. The medical device company reported $0.53 EPS for the quarter, beating the consensus estimate of $0.51 by $0.02. The medical device company had revenue of $276.90 million for the quarter, compared to analyst estimates of $254.05 million. Globus Medical had a net margin of 18.82% and a trailing twelve-month return on equity of 12.26%. The business's quarterly revenue was up 20.1% on a year-over-year basis. During the same period last year, the firm earned $0.42 earnings per share. What ETFs hold Globus Medical's stock? ETFs with the largest weight of Globus Medical (NYSE:GMED) stock in their portfolio include MFAM Small-Cap Growth ETF (MFMS), Motley Fool Small-Cap Growth ETF (TMFS), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), First Trust Indxx Medical Devices ETF (MDEV), SPDR S&P Health Care Equipment ETF (XHE), First Trust Innovation Leaders ETF (ILDR), First Trust Health Care AlphaDEX Fund (FXH) and ROBO Global Robotics & Automation ETF (ROBO). What guidance has Globus Medical issued on next quarter's earnings? Globus Medical issued an update on its FY 2023 earnings guidance on Thursday, May, 4th. The company provided earnings per share guidance of $2.30-$2.30 for the period, compared to the consensus estimate of $2.30. The company issued revenue guidance of $1.10 billion-$1.10 billion, compared to the consensus revenue estimate of $1.10 billion. What is David Demski's approval rating as Globus Medical's CEO? 47 employees have rated Globus Medical Chief Executive Officer David Demski on Glassdoor.com. David Demski has an approval rating of 61% among the company's employees. This puts David Demski in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Globus Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Globus Medical investors own include NVIDIA (NVDA), Shopify (SHOP), CrowdStrike (CRWD), Okta (OKTA), Trade Desk (TTD), Block (SQ), Tesla (TSLA), Teladoc Health (TDOC), Zoom Video Communications (ZM) and Mastercard (MA). What is Globus Medical's stock symbol? Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED." Who are Globus Medical's major shareholders? Globus Medical's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (7.49%), Wellington Management Group LLP (2.73%), State Street Corp (2.28%), William Blair Investment Management LLC (1.86%), Nuance Investments LLC (1.84%) and JPMorgan Chase & Co. (1.83%). Insiders that own company stock include Dan Lemaitre, Daniel T Scavilla, Daniel T Scavilla, David D Davidar, David M Demski, James R Tobin, James R Tobin, Keith W Pfeil, Keith W Pfeil, Kelly Huller and Robert Andrew Douglas. View institutional ownership trends. How do I buy shares of Globus Medical? Shares of GMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Globus Medical's stock price today? One share of GMED stock can currently be purchased for approximately $52.93. How much money does Globus Medical make? Globus Medical (NYSE:GMED) has a market capitalization of $5.31 billion and generates $759.12 million in revenue each year. The medical device company earns $190.17 million in net income (profit) each year or $1.97 on an earnings per share basis. How many employees does Globus Medical have? The company employs 2,600 workers across the globe. How can I contact Globus Medical? Globus Medical's mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The official website for the company is www.globusmedical.com. The medical device company can be reached via phone at (610) 930-1800, via email at investors@globusmedical.com, or via fax at 610-930-2042. This page (NYSE:GMED) was last updated on 5/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Globus Medical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.